About Zymeworks Inc.
https://www.zymeworks.comZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
CEO
Kenneth H. Galbraith
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 124
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B. Riley Securities
Buy
Stifel
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Wells Fargo
Overweight
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
ECOR1 CAPITAL, LLC
Shares:22.97M
Value:$565.53M
RUBRIC CAPITAL MANAGEMENT LP
Shares:4.71M
Value:$115.97M
BLACKROCK INC.
Shares:4.19M
Value:$103.25M
Summary
Showing Top 3 of 207
About Zymeworks Inc.
https://www.zymeworks.comZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $27.61M ▼ | $49.72M ▲ | $-19.6M ▼ | -70.99% ▼ | $-0.26 ▼ | $-15.68M ▼ |
| Q2-2025 | $48.73M ▲ | $49.4M ▼ | $2.32M ▲ | 4.76% ▲ | $0.03 ▲ | $2.59M ▲ |
| Q1-2025 | $27.11M ▼ | $52.72M ▼ | $-22.64M ▲ | -83.5% ▼ | $-0.3 ▲ | $-22.32M ▼ |
| Q4-2024 | $31.03M ▲ | $53.25M ▲ | $-23.51M ▲ | -75.75% ▲ | $-0.31 ▲ | $-18.54M ▲ |
| Q3-2024 | $16M | $50.2M | $-29.85M | -186.56% | $-0.39 | $-31.59M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $251.93M ▼ | $397.27M ▼ | $77.2M ▲ | $320.06M ▼ |
| Q2-2025 | $281.38M ▲ | $408.38M ▼ | $73.88M ▼ | $334.51M ▲ |
| Q1-2025 | $265.29M ▲ | $425.52M ▼ | $100.56M ▼ | $324.97M ▼ |
| Q4-2024 | $225.78M ▼ | $463.09M ▼ | $124.32M ▲ | $338.77M ▼ |
| Q3-2024 | $297.2M | $487.15M | $120.17M | $366.98M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-19.6M ▼ | $-31.41M ▼ | $368K ▼ | $-2.45M ▼ | $-33.42M ▼ | $-31.82M ▼ |
| Q2-2025 | $2.32M ▲ | $12.07M ▲ | $8.74M ▼ | $1.32M ▲ | $22.05M ▲ | $11.19M ▲ |
| Q1-2025 | $-22.64M ▲ | $-3.41M ▲ | $12.18M ▲ | $1.32M ▲ | $10.1M ▲ | $-3.75M ▲ |
| Q4-2024 | $-23.51M ▲ | $-41.51M ▼ | $-6.21M ▼ | $-8.64M ▲ | $-56.25M ▼ | $-41.82M ▼ |
| Q3-2024 | $-29.85M | $-5.87M | $72.26M | $-14.99M | $51.39M | $-6.87M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 Deferred Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $20.00M ▲ |
 Milestone Revenue | $0 ▲ | $10.00M ▲ | $30.00M ▲ | $20.00M ▼ |
 Option Exercise Fee | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 Research Support Payments And Other Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Upfront Fee | $20.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
Kenneth H. Galbraith
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 124
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
B. Riley Securities
Buy
Stifel
Buy
HC Wainwright & Co.
Buy
Citigroup
Buy
Wells Fargo
Overweight
JP Morgan
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
ECOR1 CAPITAL, LLC
Shares:22.97M
Value:$565.53M
RUBRIC CAPITAL MANAGEMENT LP
Shares:4.71M
Value:$115.97M
BLACKROCK INC.
Shares:4.19M
Value:$103.25M
Summary
Showing Top 3 of 207